Predominance of high-grade pathway in breast cancer development of Middle East women.
Standard
Predominance of high-grade pathway in breast cancer development of Middle East women. / Al-Kuraya, Khawla; Schraml, Peter; Sheikh, Salwa; Amr, Samir; Torhorst, Joachim; Tapia, Coya; Novotny, Hedvika; Spichtin, Hanspeter; Maurer, Robert; Mirlacher, Martina; Simon, Ronald; Sauter, Guido.
In: MODERN PATHOL, Vol. 18, No. 7, 7, 2005, p. 891-897.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Predominance of high-grade pathway in breast cancer development of Middle East women.
AU - Al-Kuraya, Khawla
AU - Schraml, Peter
AU - Sheikh, Salwa
AU - Amr, Samir
AU - Torhorst, Joachim
AU - Tapia, Coya
AU - Novotny, Hedvika
AU - Spichtin, Hanspeter
AU - Maurer, Robert
AU - Mirlacher, Martina
AU - Simon, Ronald
AU - Sauter, Guido
PY - 2005
Y1 - 2005
N2 - Recent data have suggested considerable molecular differences in cancers from various ethnical groups. As molecular features are increasingly used for predicting cancer prognosis and response to therapy, better knowledge of ethnic molecular features is important. To identify potential molecular differences between breast cancers in Europe and the Middle East, we analyzed consecutive breast cancer series from Switzerland (n=2197) and Saudi Arabia (n=204). Tissue microarrays were analyzed by fluorescence in situ hybridization for HER2, CCND1, MYC, and EGFR amplification. The data revealed marked differences between Saudi and Swiss patients. Saudi breast cancers had a markedly higher frequency of HER2 (31 vs 17%; P
AB - Recent data have suggested considerable molecular differences in cancers from various ethnical groups. As molecular features are increasingly used for predicting cancer prognosis and response to therapy, better knowledge of ethnic molecular features is important. To identify potential molecular differences between breast cancers in Europe and the Middle East, we analyzed consecutive breast cancer series from Switzerland (n=2197) and Saudi Arabia (n=204). Tissue microarrays were analyzed by fluorescence in situ hybridization for HER2, CCND1, MYC, and EGFR amplification. The data revealed marked differences between Saudi and Swiss patients. Saudi breast cancers had a markedly higher frequency of HER2 (31 vs 17%; P
M3 - SCORING: Zeitschriftenaufsatz
VL - 18
SP - 891
EP - 897
JO - MODERN PATHOL
JF - MODERN PATHOL
SN - 0893-3952
IS - 7
M1 - 7
ER -